Trial reportScientific reports2016
Correlation of serum hepcidin levels with disease progression in hepatitis B virus-related disease assessed by nanopore film based assay.
Trial report in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Review
- Taurolithocholic acid protects against viral haemorrhagic fever via inhibition of ferroptosis.Nature microbiology · 2024Article
- Review
- Iron as a therapeutic target in chronic liver disease.World journal of gastroenterology · 2023Review
- The applications of functional materials-based nano-formulations in the prevention, diagnosis and treatment of chronic inflammation-related diseases.Frontiers in pharmacology · 2023Review
- Unravelling the mechanisms by which chronic hepatitis B infection is associated with an increased risk of gestational diabetes.Frontiers in global women's health · 2023Review
- Overexpression of Hepcidin Alleviates Steatohepatitis and Fibrosis in a Diet-induced Nonalcoholic Steatohepatitis.Journal of clinical and translational hepatology · 2022Article
- Hepcidin in hepatocellular carcinoma.British journal of cancer · 2022Review
- 4210 Da and 1866 Da polypeptides as potential biomarkers of liver disease progression in hepatitis B virus patients.Scientific reports · 2021Article
- Viral Hepatitis and Iron Dysregulation: Molecular Pathways and the Role of Lactoferrin.Molecules (Basel, Switzerland) · 2020Review
- Iron and liver fibrosis: Mechanistic and clinical aspects.World journal of gastroenterology · 2019Review
- Immunonutritional consequences of different serine-type protease inhibitors in a C57BL/6 hepatocarcinoma model.Oncotarget · 2019Article
- Decreased levels of serum zonulin and copeptin in chronic Hepatitis-B patients.Pakistan journal of medical sciences · 2019Article
- Iron metabolism disorders in patients with hepatitis B-related liver diseases.World journal of clinical cases · 2018Article
- Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker.Molecular medicine (Cambridge, Mass.) · 2018Review
- Improvement of chronic hepatitis B by iron chelation therapy in a patient with iron overload: A case report.Medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
Chronic hepatitis B virus (HBV) infection often develop into cirrhosis, and both are major risk factors of hepatocellular carcinoma. However, effective approaches for the monitoring of HBV-related disease progress are still in need. Increased iron storage has an important role in HBV-related diseases. Hepcidin is a key regulator of iron homeostasis whose expression changes are often indicative of abnormal iron metabolism. There are few reports of hepcidin levels in patients with HBV infections, and the available results are inconsistent. In this study, using a recently validated nanopore silica film based method, we measured serum hepcidin levels in 46 HBV-related patients and 20 healthy controls. Patients were divided into three groups: chronic hepatitis B without cirrhosis; HBV-related cirrhosis; and HBV-related cirrhosis with hepatocellular carcinoma. Compared to healthy controls, the mean serum hepcidin level was significantly higher in CHB patients without cirrhosis, and in those with hepatocellular carcinoma, but not in those with cirrhosis. Iron-loading, viral infection and liver dysfunction are determined to be the major regulators of hepcidin in these patients. These observations suggest correlations between serum hepcidin and progression of chronic HBV infection, and may shed a new light on the development of biomarkers for HBV-related disease surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.